Richard Thompson provides a concise overview of late-onset genetic cholestasis, including the pathophysiology and genetics behind the various phenotypes that can present, in this short, animated video.
This video offers subtitles in English, Portuguese, and Spanish, which can be enabled using the subtitle icon 
in the video player.
General Information
Title: About late-onset genetic cholestasis
Release date: January 30th 2025
Estimated time to complete activity: 5 minutes
This program is made possible thanks to an independent educational grant from Ipsen
Target Audience
This activity is primarily aimed at a global audience of adult hepatologists and gastroenterologists, but is relevant to all members of the multidisciplinary team that manages late-onset genetic cholestatic patients.
Educational Objectives
After completing this activity, the participant should be better able to:
- Recognize the different phenotypes and clinical presentations of late-onset genetic cholestasis
Faculty
- Richard Thompson
King’s College London, United Kingdom
Disclosures
- Richard Thompson
Honoraria or consultation fees: CymaBay, Enanta, Genfit, GSK, Gilead, HighTide, Inipharm, Intercept, Ipsen, Madrigal, Mirum, NGM, Pfizer, 89bio, Zydus, Abbvie, Intercept, Gilead
Honoraria or consultation fees: Mirum, Ipsen, Rectify, Generation Bio, Integra, Spruce, Alnylam, Glycomine
Stocks, shares or equity: Generation Bio, Rectify, Integra
